Navigation Links
GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
Date:10/17/2007

SPOKANE, Wash., Oct. 17 /PRNewswire/ -- GenPrime, Inc. a leading provider of rapid microbial analysis technologies, has initiated multi-site clinical trials of its Bacterial Contamination Test for Platelets(TM). The test is a rapid QC device for detecting the presence of aerobic and anaerobic bacteria commonly found in contaminated platelets. The trial will generate data for filing a 510 (K) pre-market notification with the Food and Drug Administration (FDA).

"Undetected bacterial contaminants in platelets tested by culture, dipsticks and other current methods remain a significant source of sepsis and associated patient mortality and morbidity in transfusion medicine," said Buck Somes, chief executive officer of GenPrime. "We believe our technology will offer a practical and rapid solution to further mitigate this problem."

Currently, over 10 million platelet units are transfused annually into patients worldwide. It is estimated by transfusion medicine experts that as many as 1 in 2000 of these units are contaminated with bacteria. While culture based tests, which can take two to three days before results are available, have reduced the chances of contaminated platelets being infused, septic reactions continue to be reported. Traditional rapid tests such as dipsticks, staining and microscopy are highly unreliable. There remains an unmet need in the transfusion industry for a sensitive, rapid, and reliable test that is user friendly and can provide accurate, objective results.

Based on a novel, easy to use, proprietary lateral flow technology platform, GenPrime's Bacterial Contamination Test for Platelets(TM) is designed to detect all 15 organisms known to contaminate platelets. Additionally GenPrime has developed an automated test reader and software for objective result analysis and data collection. The company has completed optimization, scale-up and pre-clinical studies of the test and expects to complete the clinical trial and file the 510(K) pre-market submission to the FDA in early 2008.

For additional information, contact GenPrime, Inc., 157 South Howard, Suite 605 Spokane, WA 99201 USA, Toll Free: 1.866.624.9855, Ph: 509.624.9855, info@genprime.com

About GenPrime, Inc.

GenPrime is committed to becoming the leading provider of innovative technologies for a secure and healthy world. It currently provides products to the homeland security, and fermentation sciences industries. The Company is currently gearing up for its largest product launch yet, a highly sought after bacterial test for blood products in the healthcare and transfusion services industries. http://www.genprime.com


'/>"/>
SOURCE GenPrime, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
6. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
7. Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
8. The Power of External Influence on Our Lives
9. Demonstrations by staff in medical college against violence by external agencies
10. External Catheters Linked with decreased UTI Risk in Men
11. Corneal infections Linked to External Contamination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new ... area. The latest campaign focuses on the fight against breast cancer, fundraising for a ... accepted here . , Carmen is a loving single mother of two boys ...
(Date:2/12/2016)... San Ramon, CA (PRWEB) , ... February 12, 2016 , ... ... tissue donation in northern California and Nevada, announced a partnership with San Ramon Regional ... be transferred to the hospital’s facilities as a way to accommodate a more certain ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... For ... Dental hygienist Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 a.m. ... joined dozens of dental professionals, donating their time and skills to help hundreds of ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
(Date:2/12/2016)... ... 12, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... an upcoming Feb. 24 webinar that will discuss ways health plans and PBMs ... as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to treat ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Ky. , Feb. 12, 2016 /PRNewswire/ ... has completed a $47.1 million Series D ... Cormorant Asset Management, Hillhouse Capital Group and ... Morningside Venture Investments, AJU IB Investment, and ... be used to further advance clinical trials ...
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, today announced the submission ... New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, ... (KB0120) of Zimeta for the control of pyrexia (fever) ... --> --> The Chemistry, ...
Breaking Medicine Technology: